University of Bergen-ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

    Drugs and Aging, Vol. 39, Núm. 11, pp. 863-874

  2. Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))

    European journal of human genetics : EJHG

  3. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

    European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362

2021

  1. Correction to: Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials (European Journal of Clinical Pharmacology, (2021), 77, 1, (1-12), 10.1007/s00228-020-02951-8)

    European Journal of Clinical Pharmacology

  2. Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

    European Journal of Clinical Pharmacology, Vol. 77, Núm. 1

  3. Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers

    Clinical Infectious Diseases, Vol. 72, Núm. 11, pp. 2035-2041

2020

  1. Juvenile Sjögren's Syndrome: Clinical Characteristics With Focus on Salivary Gland Ultrasonography

    Arthritis Care and Research, Vol. 72, Núm. 1, pp. 78-87

  2. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS

    Multiple Sclerosis and Related Disorders, Vol. 43

2019

  1. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

    Nature Communications

  2. Shared heritability and functional enrichment across six solid cancers

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 1, pp. 87-100

2017

  1. Erratum: Antimicrobials: A global alliance for optimizing their rational use in intra-abdominal infections (AGORA). [World J Emerg Surg. 11, (2016) (33)] DOI: 10.1186/s13017-016-0089-y

    World Journal of Emergency Surgery

2016

  1. Antimicrobials: A global alliance for optimizing their rational use in intra-abdominal infections (AGORA)

    World Journal of Emergency Surgery, Vol. 11, Núm. 1

2009

  1. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

    The Lancet, Vol. 374, Núm. 9704, pp. 1840-1848

2007

  1. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

    Journal of the American Medical Association, Vol. 297, Núm. 12, pp. 1332-1343

2002

  1. The OPTIMAAL trial: Losartan or captopril after acute myocardial infarction [4] (multiple letters)

    Lancet